1-9 of 9
Thomas Lund
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Selinexor with Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe), Nordic Myeloma Study Group 29/21

Ida Bruun Bruun Kristensen, Hanne Marie Norseth, Diana Loigom, Henrik Gregersen, Einar Haukås, Tobias S. S. Slørdahl, Robert Schou Pedersen, Damian L. Szatkowski, Fredrik Schjesvold, Thomas Lund
Journal: Blood
Blood (2024) 144 (Supplement 1): 1988.
https://doi.org/10.1182/blood-2024-194840
Published: 2024
Journal Articles

A Phase II Study Measuring MRD Negativity after Bispecific T-Cell Redirectors Talquetamab and Teclistamab Consolidation Used in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC), Nordic Myeloma Study Group

Diana Loigom, Tobias S. S. Slørdahl, Anna Lysén, Agoston Gyula Szabo, Tine Rosenberg, Lene Kongsgaard Nielsen, Jakub Krejcik, Anne Marit Sponaas, Kristine Misund, Nicolai Jacob Wewer Albrechtsen, Jakob Nordberg Nørgaard, Thomas Lund, Sarah Leeth Hansen Farmer, Einar Haukås, Kari Lenita Falck Moore, Tatjana Tratš, Claire Albrecht, Diptendu Santra, Pavel Smirnov, Margaret Doyle, Kathleen S Gray, Fredrik Schjesvold
Journal: Blood
Blood (2024) 144 (Supplement 1): 7016.
https://doi.org/10.1182/blood-2024-203364
Published: 2024
Journal Articles

Stable MGUS and SMM Are Characterized By Distinct Senescent Features in the Pre-Malignant Plasma Cells and the Proximate Bone Microenvironment

Gabriel Alvares Borges, Marta Diaz-Delcastillo, Angelo Jose Guilatco, Fatima Ali Mustapha, Bilal El Masari, Michael Tveden Gundesen, Maja Hinge, Charlotte Guldborg Nyvold, Thomas Lund, Tamar Tchkonia, James L. Kirkland, Taxiarchis Kourelis, Matthew T. Drake, Thomas Levin Andersen, Megan Weivoda
Journal: Blood
Blood (2023) 142 (Supplement 1): 1944.
https://doi.org/10.1182/blood-2023-190375
Published: 2023
Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Niels W.C.J. Van De Donk, Monique C. Minnema, Bronno van der Holt, Fredrik Schjesvold, Ka Lung Wu, Andrea Capra, Annemiek Broijl, Wilfried W.H. Roeloffzen, Alain Gadisseur, Giuseppe Pietrantuono, Ludek Pour, Vincent H.J. van der Velden, Thomas Lund, Massimo Offidani, Mariella Grasso, Luisa Giaccone, Michele Cavo, Trine Silkjaer, Jo Caers, Sonja Zweegman, Roman Hájek, Reuben Benjamin, Annette Juul Vangsted, Mario Boccadoro, Francesca Gay, Pieter Sonneveld, Pellegrino Musto
Journal: Blood
Blood (2022) 140 (Supplement 1): 4420–4422.
https://doi.org/10.1182/blood-2022-165942
Published: 2022
Journal Articles

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

Pellegrino Musto, Monique C. Minnema, Wilfried W.H. Roeloffzen, Andrea Capra, Bronno van der Holt, Annette Juul Vangsted, Annemiek Broijl, Fredrik Schjesvold, Thomas Lund, Trine Silkjaer, Reuben Benjamin, Mariella Grasso, Ka Lung Wu, Jo Caers, Michele Cavo, Roman Hájek, Benedetto Bruno, Alain Gadisseur, Giuseppe Pietrantuono, Massimo Offidani, Luděk Pour, Pieter Sonneveld, Mario Boccadoro, Niels W.C.J. van de Donk
Journal: Blood
Blood (2022) 140 (Supplement 1): 4409–4411.
https://doi.org/10.1182/blood-2022-156390
Published: 2022
Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Niels W. C. J. Van De Donk, MD PhD, Bronno van der Holt, PhD, Fredrik H. Schjesvold, MD PhD, Ka Lung Wu, MD, Stefano Spada, Annemiek Broyl, MD PhD, Wilfried Roeloffzen, Alain Gaddiseur, Thomas Lund, MD, Monique C. Minnema, Massimo Offidani, Mariella Grasso, Niels Frost Andersen, Jo Caers, MD PhD, Benedetto Bruno, MD, Sonja Zweegman, MD PhD, Pieter Sonneveld, Roman Hajek, Prof, MD PhD, Reuben Benjamin, MD, Francesca Gay, MD, Annette Juul Vangsted, MD PhD, Pellegrino Musto
Journal: Blood
Blood (2019) 134 (Supplement_1): 693.
https://doi.org/10.1182/blood-2019-125120
Published: 2019
Journal Articles

Glucocorticoids Attenuate the Stimulatory Effect on Bone Formation by Bortezomib

Thomas Lund, Kent Søe, Niels Abildgaard, Patrick Garnero, Per Trøllund Pedersen, Jean-Marie Delaissé, Torben Plesner, MD
Journal: Blood
Blood (2008) 112 (11): 5183.
https://doi.org/10.1182/blood.V112.11.5183.5183
Published: 2008
Journal Articles

High Dose Simvastatin Has No Beneficial Effect on Markers of Bone Turn-Over in Multiple Myeloma.

Teis E. Sondergaard, MSc, Per T. Pedersen, MD, Thomas L. Andersen, MSc, Thomas Lund, MD, Patrick Garnero, PhD, Jean-Marie Delaisse, PhD, Torben Plesner, MD
Journal: Blood
Blood (2007) 110 (11): 4824.
https://doi.org/10.1182/blood.V110.11.4824.4824
Published: 2007
Journal Articles

Bortezomib Transiently Inhibits Osteoclast Resorptive Activity in Cell Culture Conditions Mimicking In Vivo Intermittent Treatment.

Patrice Boissy, PhD, Thomas Lund, MD, Thomas L. Andersen, MSc, Torben Plesner, MD, Jean-Marie Delaisse, PhD
Journal: Blood
Blood (2006) 108 (11): 3508.
https://doi.org/10.1182/blood.V108.11.3508.3508
Published: 2006